These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22331316)

  • 21. [New system combining Hyams grading system and modified Kadish stage to evaluate the progress of esthesioneuroblastoma].
    Lai YY; Lin TJ; Jiang LJ; Deng J; Zuo KJ; Zhang Y; Shi JB
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 33(7):599-602. PubMed ID: 31327194
    [No Abstract]   [Full Text] [Related]  

  • 22. Esthesioneuroblastoma: updating histologic grading as it relates to prognosis.
    Gallagher KK; Spector ME; Pepper JP; McKean EL; Marentette LJ; McHugh JB
    Ann Otol Rhinol Laryngol; 2014 May; 123(5):353-8. PubMed ID: 24668054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment modalities and outcomes of olfactory neuroblastoma.
    Song CM; Won TB; Lee CH; Kim DY; Rhee CS
    Laryngoscope; 2012 Nov; 122(11):2389-95. PubMed ID: 23070733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression patterns of Trk-A, Trk-B, GRP78, and p75NRT in olfactory neuroblastoma.
    Weinreb I; Goldstein D; Irish J; Perez-Ordonez B
    Hum Pathol; 2009 Sep; 40(9):1330-5. PubMed ID: 19386345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.
    Vuong HG; Ngo TNM; Dunn IF
    J Neurooncol; 2021 May; 153(1):15-22. PubMed ID: 33770323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient characteristics of olfactory neuroblastoma: experience from a tertiary cancer centre 2000-2016 covering Eastern Denmark.
    Gram SB; Grønhøj C; Mann H; Jakobsen KK; Kiss K; Bilde A; von Buchwald C
    APMIS; 2018 Aug; 126(8):663-666. PubMed ID: 30168622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olfactory neuroblastoma (esthesioneuroblastoma) and esthesioneuroepithelioma: histologic and immunohistochemical study.
    Taraszewska A; Czorniuk-Sliwa A; Dambska M
    Folia Neuropathol; 1998; 36(2):81-6. PubMed ID: 9757618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.
    Diensthuber M; Potinius M; Rodt T; Stan AC; Welkoborsky HJ; Samii M; Schreyögg J; Lenarz T; Stöver T
    J Neurooncol; 2008 Sep; 89(2):131-9. PubMed ID: 18431543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.
    Sharma S; Sharma MC; Johnson MH; Lou M; Thakar A; Sarkar C
    Pathol Oncol Res; 2007; 13(2):123-9. PubMed ID: 17607373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.
    Jethanamest D; Morris LG; Sikora AG; Kutler DI
    Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):276-80. PubMed ID: 17372086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
    McElroy EA; Buckner JC; Lewis JE
    Neurosurgery; 1998 May; 42(5):1023-7; discussion 1027-8. PubMed ID: 9588546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esthesioneuroblastoma--what is the optimal treatment?
    Eriksen JG; Bastholt L; Krogdahl AS; Hansen O; Joergensen KE
    Acta Oncol; 2000; 39(2):231-5. PubMed ID: 10859017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prognostic Implications of Neutrophil-to-Lymphocyte Ratio in Olfactory Neuroblastoma.
    Mocharnuk J; Daniels KE; Filimonov A; North LM; Gardner PA; Wang EW; Snyderman CH
    Otolaryngol Head Neck Surg; 2024 Oct; 171(4):1212-1216. PubMed ID: 38895868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic study of sinonasal teratocarcinosarcoma and its contrast with olfactory neuroblastoma].
    Li X; Liu HG; Xie XJ; Han YD; Li M
    Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):458-64. PubMed ID: 19035117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system.
    Saade RE; Hanna EY; Bell D
    Curr Oncol Rep; 2015 Jan; 17(1):423. PubMed ID: 25416317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract.
    Wooff JC; Weinreb I; Perez-Ordonez B; Magee JF; Bullock MJ
    Am J Surg Pathol; 2011 Dec; 35(12):1786-93. PubMed ID: 22020045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esthesioneuroblastoma: a Danish clinicopathological study of 40 consecutive cases.
    Ingeholm P; Theilgaard SA; Buchwald C; Hansen HS; Francis D
    APMIS; 2002 Sep; 110(9):639-45. PubMed ID: 12529017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined modality therapy of esthesioneuroblastoma.
    McLean JN; Nunley SR; Klass C; Moore C; Müller S; Johnstone PA
    Otolaryngol Head Neck Surg; 2007 Jun; 136(6):998-1002. PubMed ID: 17547995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic Features and Prognosis of Olfactory Neuroblastoma with Isocitrate Dehydrogenase 2 Mutations.
    Wu L; An J; Liu H
    World Neurosurg; 2022 Mar; 159():e23-e31. PubMed ID: 34856401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of failure and outcome in esthesioneuroblastoma.
    Dias FL; Sa GM; Lima RA; Kligerman J; Leoncio MP; Freitas EQ; Soares JR; Arcuri RA
    Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1186-92. PubMed ID: 14623748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.